PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 1, 2019Journal of the American College of Cardiology226 citationsOpen Access

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes

View Full Paper
DGDaníel F. GuðbjartssonGÞGuðmundur ÞorgeirssonPSPatrick Sulem

Structured PICO

Does pharmacologic reduction of Lp(a) concentration decrease CAD risk without increasing T2D risk?

I
Intervention
Pharmacologic reduction of Lp(a) concentration
O
Outcome
Risk of cardiovascular diseases (CAD) and Type 2 Diabetes (T2D)hard clinical

Pharmacologic reduction of high Lp(a) to median levels is predicted to lower CAD risk without the adverse effect of increasing T2D risk seen at very low Lp(a) levels.

Abstract

Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a) concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing T2D risk.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guðbjartsson et al. (2019) studied this question.

synapsesocial.com/papers/69d8f3e71ab91f1400bedc7bhttps://doi.org/10.1016/j.jacc.2019.10.019
Ask AI
Helpful
Bookmark
Share
View Full Paper